Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY2927088 coated · 1 trial · 4 indications
Based on radioactivity excreted in urine and feces, and vomit as a percentage of the dose to assess mass balance of total radioactivity
| Arm | Type | Description |
|---|---|---|
| Healthy male participants from Netherlands | EXPERIMENTAL | In Part 1, participants will receive a single dose of 40 mg of BAY2927088 as oral tablets on Study Day 1 approximately 30 min after a light meal, they will then receive a single dose of a microtracer not exceeding 100 ug of \[14C\]-BAY2927088 and 37 kilo becquerel (kBq) \[1000 nano Curie (nCi)\] of 14C will be administered intravenously (IV) as a 15 min infusion ending at the expected median time to maximum concentration (tmax) for the tablet (2 hours oral post-dose). After 2 days of washout, participants will move on to Part 2. In Part 2, on Study Day 1 approximately 30 min after a light meal, all enrolled participants will receive a single dose of 40 mg BAY2927088 containing approximately 3.7 MBq (100 µCi) \[14C\]-BAY 2927088 administered as an oral solution |
| Name | Type | Description |
|---|---|---|
| BAY2927088 coated tablet 10 mg | DRUG | 4 coated tablets (10 mg) per single dose 30 min after a light meal |
| [14C]-BAY2927088 solution for infusion | DRUG | IV infusion 15 min ending at 2 hours oral post-dose |
| [14C]-BAY2927088 oral solution | DRUG | After a light meal |
Inclusion Criteria: * Capable of giving signed informed consent * Participant must be 18 or age of legal maturity to 55 years of age inclusive, at the time of signing the informed consent * Participants who are overtly healthy as determined by the investigator or medically qualified designee based ...
Top 20 of 90 competitors
BAY2927088 coated is an investigational small molecule drug developed by Bayer AG for advanced non-small cell lung cancer. The coated tablet 10 mg formulation is being studied in a Phase 1 clinical trial. It is not yet approved for any indication.
BAY2927088 coated is being developed for the treatment of advanced non-small cell lung cancer, including cases with EGFR or HER2 mutations. It is currently in Phase 1 clinical development and has not been approved for any use.
BAY2927088 coated is developed by Bayer AG, which trades on the OTC market under the ticker BAYRY. Bayer is responsible for the clinical development of this investigational small molecule for advanced non-small cell lung cancer.
BAY2927088 coated is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not received FDA approval.
BAY2927088 coated has been studied in a Phase 1 trial, NCT06221475, titled "A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants." The trial enrolled 8 healthy male volunteers in the Netherlands and is now completed.